1-Methyl-4-tert.-butyl-4-hydroxy-piperidin | 13466-59-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 1-Methyl-4-tert.-butyl-4-hydroxy-piperidin
• 英文别名: 4-Tert-butyl-1-methyl-piperidin-4-ol；4-tert-butyl-1-methylpiperidin-4-ol
• CAS: 13466-59-6
• 化学式: C₁₀H₂₁NO
• 分子量: 171.283
• InChiKey: XGOWXZJBBRMQSU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  23.5
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  1-Methyl-4-tert.-butyl-4-hydroxy-piperidin 、 溴乙酰溴 生成 5-tert-butyl-1-methyl-3-oxo-4-oxa-1-aza-bicyclo[3.2.2]nonanium; bromide
  参考文献：
  名称：

  Stereochemistry of the N-Alkylation of 4-t-Butylpiperidine Derivatives^1a

  摘要：

  DOI：

  10.1021/jo01342a020

文献信息

• BICYCLIC HETEROARYL COMPOUNDS AND USES THEREOF
  申请人：Revolution Medicines, Inc.

  公开号：US20210139517A1

  公开（公告）日：2021-05-13

  The present disclosure is directed to modulators of SOS1 and their use in the treatment of disease. Also disclosed are pharmaceutical compositions comprising the same.

  本公开涉及SOS1的调节剂及其在治疗疾病中的应用。还公开了包含相同成分的药物组合物。
• SUBSTITUTED DIAZEPINE SULFONAMIDES AS BOMBESIN RECEPTOR SUBTYPE-1 MODULATORS
  申请人：Baker Robert K.

  公开号：US20100317645A1

  公开（公告）日：2010-12-16

  Certain novel substituted diazepine sulfonamides are ligands of the human bombesin receptor and, in particular, are selective ligands of the human bombesin receptor subtype-3 (BRS-3). They are therefore useful for the treatment, control, or prevention of diseases and disorders responsive to the modulation of BRS-3, such as obesity, and diabetes.

  某些新型取代二氮杂环磺酰胺是人体炸弹素受体的配体，特别是人体炸弹素受体亚型-3（BRS-3）的选择性配体。因此，它们可用于治疗、控制或预防对BRS-3调节敏感的疾病和障碍，如肥胖和糖尿病。
• Bicyclic heteroaryl compounds and uses thereof
  申请人：Revolution Medicines, Inc.

  公开号：US11168102B1

  公开（公告）日：2021-11-09

  The present disclosure is directed to modulators of SOS1 and their use in the treatment of disease. Also disclosed are pharmaceutical compositions comprising the same. Modulators of SOS1 have the following general structure of the Formula (II), or a pharmaceutically acceptable salt or a stereoisomer thereof, wherein the variables are as defined herein.

  本公开涉及 SOS1 的调节剂及其在疾病治疗中的应用。此外，还公开了由其组成的药物组合物。SOS1 的调节剂具有如下一般结构式 (II)、 或其药学上可接受的盐或立体异构体，其中变量如本文所定义。
• RIP1 INHIBITORY COMPOUNDS AND METHODS FOR MAKING AND USING THE SAME
  申请人：Chen Yan

  公开号：US20210070743A1

  公开（公告）日：2021-03-11

  Disclosed herein are kinase inhibitory compounds, such as a receptor-interacting protein-1 (RIP1) kinase inhibitor compounds, as well as pharmaceutical compositions and combinations comprising such inhibitory compounds. The disclosed compounds, pharmaceutical compositions, and/or combinations may be used to treat or prevent a kinase-associated disease or condition, particularly a RIP1-associated disease or condition.
• US8153626B2
  申请人：——

  公开号：US8153626B2

  公开（公告）日：2012-04-10